Journal
NEUROSURGICAL REVIEW
Volume 42, Issue 2, Pages 403-408Publisher
SPRINGER
DOI: 10.1007/s10143-018-01074-0
Keywords
Cavernomas; Cavernous malformations; Cavernous angiomas; Cavernous haemangiomas; Beta-blocker
Categories
Ask authors/readers for more resources
Surgery is the only therapeutic option for cerebral cavernous malformations (CCM) and is proposed, whenever possible, after haemorrhagic events, neurological symptoms, or epilepsy, radiosurgery being a controversial alternative in some cases. However, there is no treatment for non-accessible lesions, such as brainstem CCM, multiple CCM, or those located in functional areas. Propranolol, a non-selective beta-blocker used as first-line treatment for infantile haemangiomas, has proved spectacularly effective in a few cases of adult patients with CCM. We herein review the histological, in vitro data and clinical findings that support the idea of propranolol as a potential treatment for CCM. Since one retrospective study has not been conclusive, we support the idea that prospective trials are necessary.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available